Wyatt Technology has highlighted an article which outlines the benefits of quantifying protein-protein interactions (PPI) using automated dynamic light scattering (DLS) in high-throughput screening (HTS) mode to identify promising candidates for drug-like properties.
Therapeutic monoclonal antibodies (mAbs) are effective at treating chronic diseases like autoimmune disorders and cancer. Long-term stability is an important attribute of any commercial drug molecule, and of great interest in biotherapeutics. Measurements of PPI indicate colloidal stability, correlate closely to stability and viscosity at high protein concentration, and are widely used as stability-indicating parameters (SIPs) in preselecting monoclonal antibody biotherapeutic molecules and formulation conditions before long-term stability testing.
Ordinarily, PPI studies require significant quantities of sample and labour. Optimal screening processes of PPI will allow drug developers to identify and concentrate development on the most promising mAbs and formulations, saving considerable time and money.
The study, which utilised Wyatt Technology’s DynaPro Plate Reader II high-throughput DLS instrument, was published by GIT Laboratory and may be downloaded from the company’s website.
www.wyatt.com/AppNotes/DLS